Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $1.07, $0.05 better than the analyst estimate of $1.02. Revenue for the quarter came in at $907 million versus the consensus estimate of $928.18 million.

GUIDANCE:

Edwards Lifesciences sees Q4 2018 EPS of $1.05-$1.20, versus the consensus of $1.21. Edwards Lifesciences sees Q4 2018 revenue of $950-1000 million, versus the consensus of $995.4 million.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.